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1. Introduction 
a2-Macroglobulin, a major glycoprotein plasma 
and body fluids of mammals, is an inhibitor of virtu- 
ally all endoproteases. Normal human skin fibroblasts 
in culture are capabl eof internalizing large amounts 
of a2M by receptor-mediated en ocytosis [ 1 ]. This 
process was very specific, as not a2M but only a2M- 
protease complexes were recognized by the receptor 
and selectively internalized [2]. Primary amines inter- 
fered at two levels in this system: 
(i) Certain small primary amines (e.g., methylamine) 
inactivate native a2M to a state very similar to the 
one obtained with proteases: a complex which is 
recognized by the cellular eceptor [3] and by a 
monoclonal ntibody (F2B2), recognizing a neo- 
antigenic site on a2M-protease complexes [4]. 
(ii) Primary amines interfere at the cellular level with 
intracellular receptor-recycling [5]. Recycling of 
receptors was inferred from the finding that a 
rather small, but constant number of receptors at 
the plasma membrane was capable of massive 
transport of ligand [5-7] without an apparent 
large intracellular pool of receptors and without 
synthesis of new receptors. 
Bacitracin, a cyclic peptide antibiotic of bacterial 
origin, was used as another transglutaminase inhibi- 
tor, blocking clustering of fluorescently labeled a2M 
[8]. Quantitative data on ~2SIqabelled a2M binding to 
cells and cell plasma membrane preparations was 
reported in [10]: this binding was inhibited by baci- 
tracin. However, the data showed clear differences 
between the effect of bacitracin and other suspected 
transglutaminase inhibitors. 
Here we show that bacitracin is a competitive 
inhibitor of receptor-mediated en ocytosis of a2M- 
protease complexes inhibiting binding to the cellular 
receptor. Our data indicate a different mode of action 
of bacitracin as compared to the primary amine, 
mono-dansylcadaverine. 
2. Materials and methods 
Bacitracin and mono-dansylcadaverine were 
obtained from Sigma. Carrier-free Na12SI was from 
The Radiochemical Centre, Amersham. 
2.1. Cell culture 
Diploid human fibroblast cultures were obtained 
from skin biopsies of the forearm of healthy adult 
donors [11]. The cells weregrown in Dulbecco's 
modified Eagle's medium (DME; Grand Island Bio- 
logical Co., New York), containing 10% (v/v) heat- 
inactivated newborn calf serum (NCS; Sera-Lab, 
England), 1 g NaHCO3/1, 15 mM N-(tris(hydroxy- 
methyl)methyl-2-amino)ethanesulfonic acid (Tes) 
and 4-(2-hydroxymethyl)- 1 -piperazineethane-sulfonic 
acid (Hepes) buffered to pH 7.4 with 1 N NaOH. All 
cell lines were karyotyped and monitored regularly 
for mycoplasma contamination. Between passages 
10-15, an equal number of cells of each of 6 donors 
was pooled. After 2 subcultures the cells were plated 
in disposo trays (Linbro, Flow Labs., Scotland) at 
80 000 cells/well in DME containing 10% (v/v) new- 
born calf serum and placed in a 37°C incubator in an 
atmosphere of 5% CO2, 95% air and 100% humidity. 
After 48 h the cells were used in the experiments. 
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2.2. Purification of a2M 
a2M was purified from human plasma. Only plastic 
labware was used and the entire procedure was done 
at 4°C. The plasma was treated with CaC12 and 
BaSO4 as in [2]. a2M was precipitated between 4-8% 
(w/v) polyethylene glycol 6000. The precipitate was 
suspended, ialyzed againt PBS and fractionated on a 
column (5 × 94 cm) of Ultrogel ACA 22 (LKB, 
Sweden). The final purification step consisted of 
affinity chromatography on a column (2.6 × 90 cm) 
of Blue Sepharose (Pharmacia, Sweden). Eluent was a 
sodium phosphate buffer (25 mM, pH 7.7). Quantita- 
tion of a2M after each step and in column fractions 
was carried out by rocket immunoelectrophoresis 
[ 12]. Protein was determined as in [ 13], with bovine 
serum albumin as standard. A typical purification 
procedure starting with 300 ml plasma resulted in a 
preparation containing 97% a2M, in a yield of 58%. 
2.3.12sI-a2M and a2sI-a~M- trypsin complexes 
o~2M was iodinated using Na12SI and chloramine-T 
as in [2]. After labeling, a2M was reacted with a 
3-fold excess crystalline trypsin (on a molar basis). 
Complexes were separated from free trypsin as in [2]. 
Labeled a2M was stored at 4°C. 
2.4. Uptake and degradation fa2M at 37°C 
The cell layers grown in DME-newborn calf serum 
were washed 3 times with 1 ml serum-free medium 
without HCO3, followed by a 15 min incubation at 
37°C in this medium. Tile medium was then replaced 
by 0.5 ml prewarmed DME containing 12sI-a2M- 
trypsin at the appropriate concentration. The trays 
were kept at 37°C for the desired time period, the 
medium was removed, the cell layers were washed 
4 times with ice-cold PBS, and 0.5 ml crystalline tryp- 
sin (0.5 mg/ml) was added for 5 min at 37°C. The 
trypsinized cells were removed and each well was 
washed with 0.5 ml cold PBS and this wash-fluid was 
combined with the cell suspension. The cell suspen- 
sion was centrifuged (800 X g, 10 min) and radio- 
activity in cell pellet and supernatant was counted in 
an automatic scintillation counter (PRIAS, Packard). 
Intracellular degradation of 12sI-a2M was followed 
over a 4 h period. The cell layers were pulsed for 
30 rain with 12SI-a2M-trypsin, washed 3 times and 
further incubated in complete medium containing 
10% (v/v) serum. At the time periods indicated, the 
cell layers were trypsinized as described above and 
counted. 
2.5. Binding of 12sI-azM at 4°C 
Binding studies were carried out at 4°C with the 
trays placed on crushed ice in a 4°C refrigerator. The 
incubation media used in binding studies contained 
albumin (2 mg/ml) to decrease non-specific binding 
of a2M. The cell layers were washed 3 times with cold 
DME containing bovine serum albumin (0.2%, w/v) 
and left in this medium for 15 min. The medium was 
removed and 0.5 ml DME containing 12sI-a2M-tryp- 
sin (2/ag/ml) was added. Specific binding was calcu- 
lated from data with excess unlabeled a2M-trypsin as 
in [2]. 
3.Results 
Bacitracin proved a very effective inhibitor of 
receptor-mediated endocytosis of 12sI-a2M-trypsin 
complexes by fibroblasts in culture (fig.l). In the 
presence of 0.25 mg bacitracin/ml endocytosis was 
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Fig.1. Effect of  concentration of  bacitracin on receptor- 
mediated endocytosis of 125 I-labeled a 2 M-t ryps in  complexes. 
Normal human fibroblast cell layers were preincubated with 
bacitracin in medium or with medium only for 30 min. After 
washing with medium, ~2s I-labeled a2 M-tryps in  was added 
(50 gg/ml in medium). After 30 min at 37°C cells were 
washed and intracellutar content of  label was determined. 
Bacitracin was present during the assay (o) at the concentra- 
tions indicated or cell layers were pretreated with bacitracin 
(30 rain, 37°C) while the drug was not present during the 
assay (o). Data are the mean of duplicate determinations and 
are expressed relative to untreated cell layers. 
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inhibited by ~50%. When the cell layers were pre- 
treated with bacitracin and subsequently examined 
for endocytosis n the absence of the drug, no inhibi- 
tion was observed (fig.l). As this latter finding was 
completely different from our observations on the 
effect of primary amines on receptor-mediated endo- 
cytosis [5], we examined in the same set of experi- 
ments the effect of bacitracin on endocytosis at 37°C 
and on receptor binding at 4°C, in comparison to 
mono-dansylcadaverine (m-DNSC) (table 1). 
It is clear from these data that bacitracin was an 
effective inhibitor of the endocytosis and the binding 
of a2sI-azM-trypsin but only when the drug was 
present during the assay. Pretreatment of the cells 
did not affect endocytosis or binding. This was very 
much unlike m-DNSC which was only maximally 
effective when cells were pretreated for at least 
30 rain [5]. Moreover, the mere presence of m-DNSC 
at 4°C did not affect binding of azM-trypsin while 
bacitracin inhibited binding 60% under these condi- 
tions (table 1). 
Table 1 
Effect of bacitracin and mono-dansylcadaverine on internali- 
zation and binding of a2M-trypsin complexes 
Bacitracin m-DNSC 
(1 mg/ml) (0.2 raM) 
Endocytosis (37°C) 
pre-30 min 104 43 
present 22 70 
pre-30 min + present 24 38 
Binding (4 ° C) 
pre-30 min 97 48 
present 41 99 
pre-30 min + present 40 37 
Normal human fibroblast monolayers were examined for 
receptor-mediated en ocytosis at37°C or for receptor-bind- 
ing at 4°C with 12Slqabeled a2M-trypsin complexes. Endo- 
cytosis at 37°C was determined for 30 rain with 100 qg 
ligand/ml medium. Binding was measured after 4 h at 4°C 
with 1 t~g 125 l.a2 M-trypsin/ml medium. Non-specific binding 
was determined by addition of 100 t~g a2M-trypsin/ml. 
Results are expressed relative to controls receiving no drugs, 
but under otherwise identical conditions. Pretreatment of cell 
layers was at 37°C for 30 min for both endocytosis and for 
binding. For measurements of endocytosis cell layers were 
subsequently washed with warm medium, containing the 
drug or not when indicated. For measurements of binding, 
cell layers were washed with ice cold medium while trays 
were placed on crushed ice. After 15 min the assay was 
started by addition of labeled a2M-trypsin 
The type of inhibition of both drugs on receptor- 
mediated endocytosis was examined (fig.2). Whereas 
m-DNSC clearly decreased the maximal rate of endo- 
cytosis of ~2M-trypsin, bacitracin did not. From the 
double-reciprocal plot it would appear that bacitracin 
is a purely competitive inhibitor of endocytosis. 
As these data point to inhibition of binding to the 
receptor, we examined whether bacitracin could 
inhibit the binding of the monoclonal antibody F2B2. 
This antibody binds to the receptor-recognition site 
on a2M-protease complexes, thus preventing the lat- 
ter from being internalized by fibroblasts [4]. The 
results indicated that bacitracin even at concentra- 
tions much higher than those used in the cellular 
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Fig.2. Kinetic parameters of receptor-mediated en ocytosis, 
in the presence of bacitracin or mono-dansylcadaverine. Dou-
ble reciprocal plot of receptor-mediated en ocytosis with 
concentration f 12Slqabeled a2M-trypsin as indicated, under 
control conditions (e), in th~ presence of 0.25 mg bacitra- 
cin/ml (o) or in the presence of 0.2 mM mono-dansylcadaver- 
ine (o). For m-DNSC only, cells were also pretreated with the 
same concentration for 30 min. Data are the mean of dupli- 
cate determinations on separate cell layers. 
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Fig.3. Effect of bacitracin on binding of the monoclonal 
antibody F2B2, to c%M-complexes, c%M was reacted with 
methylamine (25 mM, Tris-HC1 (pH 8.0)). Rate electropho- 
resis on 5% polyacrylamide g l as in [3] indicated a 2 M-MA 
complexes to be formed with a small amount of slow form 
c%M still present (4). When a2M-complexes are reacted with 
excess F2B2, subsequent rate electrophoresis hows the pat- 
tern as in (3): fast form a2M is shifted to a slower mobility 
(see also [4 ]). When antibody is added to a s M-complexes in
the presence of bacitracin o differences in the pattern are 
observed: (1) 5 mg bacitracin/ml; (2) 1 mg bacitracin/ml. 
Similar patterns were observed with c~M trypsin complexes, 
Abbreviations: a2M. C, a2M-complex; F2B2, monoclonal 
antibody (see text); a 2 M. F2B2, immune complex of a2M- 
complex and monoclonal ntibody. Bacitracin migrates at the 
dye front. 
experiments, did not inhibit binding of the mono- 
clonal antibody to a2M-complexes (fig.3). 
Finally, we examined the effect of bacitracin on 
intracellular degradation of J2SIqabeled a2M-trypsin 
complexes, internalized by receptor-mediated endo- 
cytosis. Under control conditions intraceUular half- 
life of the complexes was 2.1 h confirming [2,5]. In 
the continuous presence of 0.25 mg bacitracin/ml 
intracellular half-life was 2.5-2.7 h. 
4. Discussion 
These data confirm that bacitracin interferes with 
receptor-mediated endocytosis of a2M-trypsin com- 
plexes by normal human fibroblasts in culture [10]. 
The mode of action of bacitracin is however different 
from m-DNSC: 
(i) Bacitracin does not require preincubation with 
the cells to become inhibitory; 
(ii) Bacitracin inhibits binding of azM-trypsin to the 
receptor; 
(iii) Bacitracin inhibits endocytosis n a competitive 
fashion; 
(iv) Bacitracin does not appreciably affect intracellu- 
lar degradation of endocytozed a2M. 
Taken together these findings indicate that bacitracin 
is only effective xtracellulady by inhibiting the bind- 
ing of a2M-complexes to the receptor, whereas 
m-DNSC is only effective intracellularly and does not 
affect binding of a2M-complexes to the receptor. 
Mono-dansylcadaverine a dother primary amines 
inhibit the recycling of a2M-receptors in fibroblasts 
[5]. This was refuted on the basis that bacitracin and 
other transglutaminase inhibitors inhibited internali- 
zation of a2M [10] and binding of a2M to plasma 
membranes [9]. These authors explained inhibition 
by bacitracin [ 10], as an inhibition of receptor-clus- 
tering at 0°C as the result of an enzymatic (transglu- 
taminase-mediated) process, while other transgluta- 
minase inhibitors were not effective under the same 
conditions. Furthermore, inhibition of binding of 
a2M to plasma membranes by m-DNSC was described 
in [9] while the same drug was not effective on bind- 
ing to intact cells [ 10]. 
It must be clear from these results that both drugs 
interfere with receptor-mediated endocytosis of 
a2M-complexes, but at different steps in the process. 
Therefore it is unlikely that bacitracin and m-DNSC 
block receptor-mediated endocytosis by virtue of 
their being transglutaminase inhibitors, as claimed 
[9,10]. An explanation of all findings would be that 
bacitracin interferes directly with binding of a2M- 
complexes to the cellular eceptor, while primary 
amines uch as m-DNSC act intracellularly on recep- 
tor-recycling [5]. The latter process might or might 
not be mediated by a transglutaminase activity [5]. 
The difference in mode of action between bacitracin 
and m-DNSC is stressed further, as preliminary results 
indicate that bacitracin is not an effective inhibitor of 
fibroblast ransglutaminase activity (unpublished). 
Our finding that bacitracin is a competitive inhib- 
tor of azM-endocytosis is quite exciting from a bio- 
chemical point of view. The question arises whether 
bacitracin binds to the receptor or to the a2M-com- 
plexes. In this regard it is of some interest hat baci- 
tracin is a chelator of bivalent metal ions. Ca 2+ seems 
involved in receptor-mediator endocytosis of a2M- 
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complexes probably at the binding step [10]. How- 
ever, it is well known that a2M itself binds metals, 
such as Ca 2÷ and Zn 2÷, and it is not clear whether 
Ca 2÷ is needed at the cellular eceptor or on the 
ligand, or on both. AS bacitracin binds Zn 2÷ more 
effectively than Ca 2÷ [14], the metal chelating char- 
acteristics of bacitracin are worth consideration. Our 
findings that bacitracin does not affect the recogni- 
tion of a2M-complexes by the monoclonal antibody, 
F2B2, might be explained by such a mechanism. If
the metal-chelating properties of bacitracin are not 
involved, which remains to be determined, other 
structural features uch as the cyclic peptide or the 
thiazoline ring of bacitracin eed further considera- 
tion. Preliminary experiments, in which bacitracin 
was hydrolyzed in acid, known to open the thiazoline 
ring [15], indicated this structure not to be important 
in inhibitions. Other derivatives would yield more 
information on the type of interaction producing 
inhibition. This kind of reasoning will direct further 
experiments o understand the exact nature of the 
~2M-protease complex interaction with the cellular 
receptor. This implies of course that bacitracin is 
somehow specific for a2M-binding to the cellular 
receptor. Apparently, receptor-mediated endocytosis 
of low density l ipoprotein is not affected by bacitra- 
c in [  16]. Other fibroblast surface antigens might 
however be acted upon, as we found bacitracin to be 
a very potent inhibitor of aminopeptidase M (unpub- 
lished) shown to be present at the fibroblast plasma 
membrane [ 17,18]. 
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